The objective of the research was to investigate the content of insulin, insulin-like growth factor-1 and phosphorylated protein kinase proline-rich Akt substrate of 40kDa and to determine their role in the activation of oncogenesis processes in women with type 2 diabetes mellitus and endometrial cancer.
Materials and methods. There were examined 46 women who were divided into 4 groups: Group I included healthy women; Group II comprised women with type 2 diabetes mellitus; Group III included women with endometrial cancer; Group IV comprised women with endometrial cancer and co-existent type 2 diabetes mellitus. The levels of insulin, insulin-like growth factor-1, phospho- proline-rich Akt substrate of 40kDa were determined by immune-enzyme analysis. The compensation of diabetes mellitus was evaluated by hemoglobin A1c level using method of ion-exchange chromatography. The results obtained were analyzed using statistical analysis.
Results. Women of all study groups had increased levels of insulin and insulin-like growth factor-1 as compared to the control group (p<0.05). The level of phospho-proline-rich Akt substrate of 40kDa increased in the patients of Group II (p<0.05) and the patients of Group III (p<0.05) and decreased in the patients of Group IV (p<0.05). According to correlation analysis, phospho-proline-rich Akt substrate of 40kDa was found to correlate with body mass index, insulin and insulin-like growth factor-1 in Group II, body mass index and insulin-like growth factor-1 in Group III and body mass index in Group IV (p<0.05).
Conclusions. There was found an association between type 2 diabetes mellitus and endometrial cancer through obesity, hyperinsulinemia and insulin-like growth factor-1. The increase in phospho- proline-rich Akt substrate of 40kDa level was a sign of activation of mTOR and oncogenesis processes in the patients with type 2 diabetes mellitus. The decrease in phospho-proline-rich Akt substrate of 40kDa in the patients with endometrial cancer and co-existent type 2 diabetes mellitus can be explained by the influence of other intracellular regulatory systems or the effects of antidiabetic drugs, that requires additional study.
Andersen JN, Sathyanarayanan S, Di Bacco A et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010;2(43):43ra55. DOI: https://doi.org/10.1126/scitranslmed.3001065 [PMid:20686178]
Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol. 2013;87(3):201-23. DOI: https://doi.org/10.1016/j.critrevonc.2013.01.005 [PMid:23434537 PMCid:PMC4095988]
Carling D. AMPK signalling in health and disease. Curr Opin Cell Biol. 2017;45:31-37. DOI: https://doi.org/10.1016/j.ceb.2017.01.005 [PMid:28232179]
Chae YK, Arya A, Malecek MK et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767-40780. DOI: https://doi.org/10.18632/oncotarget.8194
Chen L, Chen R, Wang H et al. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol. 2015;2015:508409. DOI: https://doi.org/10.1155/2015/508409 [PMid:26136779 PMCid:PMC4468292]
Dai C, Li N, Song G et al. Insulin-like growth factor 1 regulates growth of endometrial carcinoma through PI3k signaling pathway in insulin-resistant type 2 diabetes. American Journal of Translational Research. 2016;8(8):3329-3336.
Emons G, Beckmann MW, Schmidt D et al. Uterus commission of the Gynecological Oncology Working Group (AGO). New WHO Classification of Endometrial Hyperplasias. Geburtshilfe Frauenheilkd. 2015;75(2):135-136. DOI: https://doi.org/10.1055/s-0034-1396256 [PMid:25797956 PMCid:PMC4361167]
Farese RV, Sajan MP. Metabolic functions of atypical protein kinase C: "good" and "bad" as defined by nutritional status. Am J Physiol Endocrinol Metab. 2010;298(3):385-394. DOI: https://doi.org/10.1152/ajpendo.00608.2009 [PMid:19996389 PMCid:PMC3774273]
Gallagher EJ, Le Roith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci. 2011;1243:54-68. DOI: https://doi.org/10.1111/j.1749-6632.2011.06285.x [PMid:22211893]
García-Jiménez C, Gutiérrez-Salmerón M, Chocarro-Calvo A et al. From obesity to diabetes and cancer: epidemiological links and role of therapies. Br J Cancer. 2016;114(7):716-722. DOI: https://doi.org/10.1038/bjc.2016.37 [PMid:26908326 PMCid:PMC4984860]
Harding JL, Shaw JE, Peeters A et al. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264-270. DOI: https://doi.org/10.2337/dc14-1996 [PMid:25488912]
Hendriks SH, Schrijnders D, van Hateren KJ et al. Association between body mass index and obesity-related cancer risk in men and women with type 2 diabetes in primary care in the Netherlands: a cohort study (ZODIAC-56). BMJ Open. 2018 ;8(1):e018859. DOI: https://doi.org/10.1136/bmjopen-2017-018859 [PMid:29371278 PMCid:PMC5786141]
Howell JJ, Hellberg K, Turner M et al. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25(2):463-471. DOI: https://doi.org/10.1016/j.cmet.2016.12.009 [PMid:28089566 PMCid:PMC5299044]
Hua F, Yu JJ, Hu ZW. Diabetes and cancer, common threads and missing links. Cancer Lett. 2016;374(1):54-61. DOI: https://doi.org/10.1016/j.canlet.2016.02.006 [PMid:26879686]
Jian Gang P, Mo L, Lu Y, Runqi L et al. Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. Endocr Res. 2015;40(1):54-61. DOI: https://doi.org/10.3109/07435800.2014.934961 [PMid:25105463]
Vatseba TS, Sokolova LK. Breast cancer in women with diabetes mellitus type 2. World of Medicine and Biology. 2019;2(68):30-34. DOI: https://doi.org/10.26724/2079-8334-2019-2-68-30-34
Wang H, Zhang Q, Wen Q et al. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal. 2012;24(1):17-24. DOI: https://doi.org/10.1016/j.cellsig.2011.08.010 [PMid:21906675]
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.